{"id":1097,"date":"2016-08-24T17:36:33","date_gmt":"2016-08-24T12:06:33","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1097"},"modified":"2021-07-24T12:56:31","modified_gmt":"2021-07-24T07:26:31","slug":"business-cocktail-2","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2","title":{"rendered":"Bristol Meyers Squibb &#038; AbbVie partner; BioLineRx\u2019s collaboration with MD Anderson Cancer Centre; Partnership between Regeneron Pharmaceuticals and Adicet Bio; Immunotherapy Target Unique Mutations in cancer"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a101f807ca3a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a101f807ca3a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2\/#Partnership_between_Bristol_Meyers_Squibb_and_AbbVie_aims_to_evaluate_the_Combination_of_Rova-T_plus_Opdivo_and_Opdivo_plus_Yervoy_Regimen\" >Partnership between Bristol Meyers Squibb and AbbVie aims to evaluate the Combination of Rova-T plus Opdivo and Opdivo plus Yervoy Regimen<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2\/#BioLineRxs_collaboration_with_MD_Anderson_Cancer_Centre_Texas_is_set_to_assess_the_effectiveness_of_2_Immunotherapies\" >BioLineRx\u2019s collaboration with MD Anderson Cancer Centre, Texas is set to assess the effectiveness of 2 Immunotherapies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2\/#Partnership_between_Regeneron_Pharmaceuticals_and_Adicet_Bio_may_result_in_new_treatment_options_for_certain_Cancers\" >Partnership between Regeneron Pharmaceuticals and Adicet Bio may result in new treatment options for certain Cancers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2\/#Immunotherapy_Targeting_Unique_Mutations_in_a_Cancer_to_be_developed_through_Alliance_between_Amgen_and_Advaxis\" >Immunotherapy Targeting Unique Mutations in a Cancer to be developed through Alliance between Amgen and Advaxis<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: left;\"><span class=\"ez-toc-section\" id=\"Partnership_between_Bristol_Meyers_Squibb_and_AbbVie_aims_to_evaluate_the_Combination_of_Rova-T_plus_Opdivo_and_Opdivo_plus_Yervoy_Regimen\"><\/span>Partnership between Bristol Meyers Squibb and AbbVie aims to evaluate the Combination of Rova-T plus Opdivo and Opdivo plus Yervoy Regimen<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed extensive-stage small cell lung cancer (SCLC). The collaboration is aimed to evaluate safety, tolerability and efficacy of Bristol-Myers Squibb\u2019s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) in combination with AbbVie\u2019s investigational biomarker-specific antibody drug Rova-T (rovalpituuzumab tesirine) in a phase I\/II clinical trial,. The combination will be tested to promote targeted cell killing and antigen release with an enhanced immunotherapy effect.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"BioLineRxs_collaboration_with_MD_Anderson_Cancer_Centre_Texas_is_set_to_assess_the_effectiveness_of_2_Immunotherapies\"><\/span>BioLineRx\u2019s collaboration with MD Anderson Cancer Centre, Texas is set to assess the effectiveness of 2 Immunotherapies<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">BioLineRx is set to investigate how it\u2019s new drug candidate, BL-8040, interacts with Keytruda (pembrolizumab), Merck\u2019s blockbuster drug. The study will be conducted as a investigator-sponsored study, and would be a part of the clinical research that is being conducted by Merck and MD Anderson Cancer Center, as they are involved in a clinical research collaboration for studying the effect of Keytruda in combination with several other drugs and treatments. The open label Phase 2 study is expected to start later this year.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Partnership_between_Regeneron_Pharmaceuticals_and_Adicet_Bio_may_result_in_new_treatment_options_for_certain_Cancers\"><\/span>Partnership between Regeneron Pharmaceuticals and Adicet Bio may result in new treatment options for certain Cancers<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">A strategic collaboration and licensing agreement between Regeneron Pharmaceuticals and Adicet Bio is set to develop immune cell therapeutics like CAR T cell and TCR in several hematological and solid tumors. These companies have shared that the collaboration aims to access and improve the therapy for eliminating solid tumors through Adicet\u2019s cell platform now under development, and innovative targeting approaches. Adicet is expected to pay an upfront payment of $25 million to Regeneron, as well as research funding over five years.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Immunotherapy_Targeting_Unique_Mutations_in_a_Cancer_to_be_developed_through_Alliance_between_Amgen_and_Advaxis\"><\/span>Immunotherapy Targeting Unique Mutations in a Cancer to be developed through Alliance between Amgen and Advaxis<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Partnership between Amgen and Advaxis will lead to the development and commercialization of Advaxis\u2019 Adxs-Neo, which is a potential cancer immunotherapy. This therapy is right now in its preclinical development stage. This alliance benefits from the expertise Amgen has in immuno-oncology, and Advaxis\u2019 MINE (My Immunotherapy Neo-Epitopes) program. The MINE platform is designed to activate the immune system of the patient to respond against unique mutations present in the tumor. They will also make an upfront payment of $40 million to Advaxis, and will also purchase $25 million of Advaxis common stock. Apart from that, Amgen is said to take responsibility of funding clinical and commercial activities. Advaxis will also receive development, regulatory and sales milestone payments of up to $475 million, and will develop the Adxs-Neo through proof of concept studies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Partnership between Bristol Meyers Squibb and AbbVie aims to evaluate the Combination of Rova-T plus Opdivo and Opdivo plus Yervoy Regimen Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed extensive-stage small cell lung cancer (SCLC). The collaboration is aimed to evaluate safety, tolerability [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1105,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[56,17286,3243,831,1076,3454,137,315,17285,1510],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-1097","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbvie","tag-adicet-bio","tag-advaxis","tag-amgen","tag-biolinerx","tag-bristol-meyers-squibb","tag-cancer","tag-immunotherapy","tag-md-anderson-cancer-centre","tag-regeneron-pharmaceuticals","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bristol Meyers Squibb &amp; AbbVie partner; BioLineRx\u2019s collaboration<\/title>\n<meta name=\"description\" content=\"Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bristol Meyers Squibb &amp; AbbVie partner; BioLineRx\u2019s collaboration\" \/>\n<meta property=\"og:description\" content=\"Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-08-24T12:06:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021736\/maxresdefault-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bristol Meyers Squibb & AbbVie partner; BioLineRx\u2019s collaboration","description":"Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2","og_locale":"en_US","og_type":"article","og_title":"Bristol Meyers Squibb & AbbVie partner; BioLineRx\u2019s collaboration","og_description":"Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed....","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-08-24T12:06:33+00:00","article_modified_time":"2021-07-24T07:26:31+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021736\/maxresdefault-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2","name":"Bristol Meyers Squibb & AbbVie partner; BioLineRx\u2019s collaboration","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021736\/maxresdefault-1.jpg","datePublished":"2016-08-24T12:06:33+00:00","dateModified":"2021-07-24T07:26:31+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-2"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-2#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021736\/maxresdefault-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021736\/maxresdefault-1.jpg","width":1280,"height":720},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021736\/maxresdefault-1-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Adicet Bio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Advaxis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BioLineRx<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bristol Meyers Squibb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Immunotherapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MD Anderson Cancer Centre<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron Pharmaceuticals<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">Adicet Bio<\/span>","<span class=\"advgb-post-tax-term\">Advaxis<\/span>","<span class=\"advgb-post-tax-term\">Amgen<\/span>","<span class=\"advgb-post-tax-term\">BioLineRx<\/span>","<span class=\"advgb-post-tax-term\">Bristol Meyers Squibb<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Immunotherapy<\/span>","<span class=\"advgb-post-tax-term\">MD Anderson Cancer Centre<\/span>","<span class=\"advgb-post-tax-term\">Regeneron Pharmaceuticals<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 24, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 24, 2016 5:36 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1097"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1097\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1105"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1097"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1097"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}